South Korea’s ambitious plan to improve corporate governance standards got a boost after the parliament voted to approve changes that will help protect the rights of minority shareholders https://t.co/OBq2Hb27ea ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Napco Security Technologies, Inc. (NASDAQ: NSSC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Napco Security caused the company to misrepresent Napco’s overall expected growth and strength in the Company’s hardware division, including, among other things, confidence in Napco’s ability to achieve i ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of NET Power Inc. (NYSE: NPWR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at NET Power caused the company to misrepresent or fail to disclose that (i) Net Power was unlikely to complete Project Permian on schedule, and the project was likely to be significantly more expensive than had been represented ...

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

🔥 NEW: Metaplanet is now the 5th largest corporate holder of Bitcoin. https://t.co/uLd7KVAdna ...

SAN DIEGO, July 1, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit.  Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta' ...

ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Petco’s business, operations, and prospects, including allegations that: (i) Petco’s pandemic-related tailwinds were unsustainable, as was its business model of selling primarily p ...

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].